Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

mAbs

Volumn 9, Issue 5, 2017, Pages 792-800

  Huang, Yunda ^a,b   Zhang, Lily ^a   Ledgerwood, Julie ^c   Grunenberg, Nicole ^a   Bailer, Robert ^c   Isaacs, Abby ^a   Seaton, Kelly ^d   Mayer, Kenneth H ^e   Capparelli, Edmund ^f   Corey, Larry ^a   Gilbert, Peter B ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e FENWAY INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Body weight; multiple dose; time concentration curve; two compartment; VRC01 serum concentration

Indexed keywords

HEMOGLOBIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VRC01; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VRC01 MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LOADING DRUG DOSE; MALE; MEASUREMENT PRECISION; PHARMACOKINETICS; SIMULATION; SINGLE DRUG DOSE; STRUCTURE MODEL INDEX; ADOLESCENT; BIOLOGICAL MODEL; DOSE RESPONSE; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 85019570515     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2017.1311435     Document Type: Article

References (29)

1. World Health Organization. HIV/AIDS Fact Sheet. 2016 Jul. [accessed 2016Jul22]. http://www.who.int/mediacentre/factsheets/fs360/en/
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505; PMID:21767103; https://doi.org/10.1056/NEJMoa1105243
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99; PMID:21091279; https://doi.org/10.1056/NEJMoa1011205
4. National Institutes of Health. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents:Limitations to treatment safety and efficacy:Adverse effects of antiretroviral agents. 2014 May 1. [accessed 2015Feb17]. http://aidsinfo.nih.gov/guidelines
5. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13-9; PMID:22333749; https://doi.org/10.1097/QAD.0b013e3283522272
6. Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, Safrit JT, Graham BS, Snow W. HIV monoclonal antibodies:A new opportunity to further reduce mother-to-child HIV transmission. PLoS Med 2014; 11:e1001616; PMID:24714363; https://doi.org/10.1371/journal.pmed.1001616
7. Nakamura KJ, Cerini C, Sobrera ER, Heath L, Sinkala M, Kankasa C, Thea DM, Mullins JI, Kuhn L, Aldrovandi GM. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS 2013; 27:337-46; PMID:23296195; https://doi.org/10.1097/QAD.0b013e32835cadd6
8. Russell ES, Ojeda S, Fouda GG, Meshnick SR, Montefiori D, Permar SR, Swanstrom R. Short communication:HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. AIDS Res Hum Retroviruses 2013; 29:511-5; PMID:23075434; https://doi.org/10.1089/aid.2012.0197
9. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-7; PMID:20616231; https://doi.org/10.1126/science.1192819
10. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-61; PMID:20616233; https://doi.org/10.1126/science.1187659
11. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 2014; 6:243ra88; PMID:24990883; https://doi.org/10.1126/scitranslmed.3008992
12. Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, Ko SY, Chen X, Schmidt SD, Haase AT, et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J Virol 2015; 89:5895-903; PMID:25787288; https://doi.org/10.1128/JVI.00210-15
13. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 2016; 533:105-9; PMID:27120156; https://doi.org/10.1038/nature17677
14. Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P. Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials. Stat Commun Infect Dis In press.
15. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196:1304-12; PMID:17922394; https://doi.org/10.1086/522428
16. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615-7; PMID:22437237; https://doi.org/10.1093/cid/cis238
17. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 2015; 7:319ra206; PMID:26702094; https://doi.org/10.1126/scitranslmed.aad5752
18. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 2015; 182:289-301; PMID:26332605; https://doi.org/10.1111/cei.12692
19. European Medicines Agency. Guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms. 2013 Feb 21. [accessed 2016Feb28]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500140482.pdf
20. IMpact Study Group-RSV. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7; PMID:9738173; https://doi.org/10.1542/peds.102.3.531
21. Homaira N, Rawlinson W, Snelling TL, Jaffe A. Effectiveness of palivizumab in preventing RSV hospitalization in high risk children:A Real-World perspective. Int J Pediatr 2014; 2014:571609; PMID:25548575; https://doi.org/10.1155/2014/571609
22. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49:1012-24; PMID:19620385; https://doi.org/10.1177/0091270009337512
23. Davda JP, Dodds MG, Gibbs MA, Wisdom W, Gibbs J. A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design. MAbs 2014; 6:1094-102; PMID:24837591; https://doi.org/10.4161/mabs.29095
24. Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 2012; 51:119-35; PMID:22257150; https://doi.org/10.2165/11596370-000000000-00000
25. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr., Leney M, Sloan S, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205; PMID:20089970; https://doi.org/10.1056/NEJMoa0907635
26. Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl M, Pomposelli JJ, Pomfret EA, et al. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation:a randomized controlled study. Am J Transplant 2013; 13:1047-54; PMID:23356386; https://doi.org/10.1111/ajt.12083
27. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-45; PMID:19319142; https://doi.org/10.1038/nri2524
28. Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JC, Parrish EH, Learn GH, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 2016; 352:997-1001; PMID:27199429; https://doi.org/10.1126/science.aaf0972
29. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75:85-94; PMID:15212851; https://doi.org/10.1016/j.cmpb.2003.11.003